Laboratory Corporation of America Holdings Logo

Laboratory Corporation of America Holdings

0JSY.L

(0.2)
Stock Price

227,98 USD

8.55% ROA

4.79% ROE

31.29x PER

Market Cap.

19.031.667.930,00 USD

57.44% DER

16.14% Yield

3.24% NPM

Laboratory Corporation of America Holdings Stock Analysis

Laboratory Corporation of America Holdings Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Laboratory Corporation of America Holdings Fundamental Stock Analysis
# Analysis Rating
1 Dividend Growth

With a history of consistent dividend increases over the last three years, the company has proven to be a reliable choice for investors seeking reliable income.

2 ROE

Unidentified ROE

3 ROA

Unidentified ROA

4 PBV

Unidentified ROA

5 DER

Unidentified DER

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Graham Number

Unidentified Graham Number

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Laboratory Corporation of America Holdings Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Laboratory Corporation of America Holdings Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Laboratory Corporation of America Holdings Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Laboratory Corporation of America Holdings Revenue
Year Revenue Growth
2012 5.671.400.000
2013 5.808.300.000 2.36%
2014 6.011.600.000 3.38%
2015 8.505.700.000 29.32%
2016 9.552.900.000 10.96%
2017 10.308.000.000 7.33%
2018 11.333.400.000 9.05%
2019 11.554.800.000 1.92%
2020 13.978.500.000 17.34%
2021 16.120.900.000 13.29%
2022 14.876.800.000 -8.36%
2023 12.227.200.000 -21.67%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Laboratory Corporation of America Holdings Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Laboratory Corporation of America Holdings General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Laboratory Corporation of America Holdings EBITDA
Year EBITDA Growth
2012 1.247.200.000
2013 1.203.500.000 -3.63%
2014 1.152.500.000 -4.43%
2015 1.655.800.000 30.4%
2016 1.788.000.000 7.39%
2017 1.823.400.000 1.94%
2018 1.819.000.000 -0.24%
2019 1.862.900.000 2.36%
2020 3.478.000.000 46.44%
2021 3.951.100.000 11.97%
2022 2.663.500.000 -48.34%
2023 1.663.600.000 -60.1%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Laboratory Corporation of America Holdings Gross Profit
Year Gross Profit Growth
2012 2.249.700.000
2013 2.223.200.000 -1.19%
2014 2.203.100.000 -0.91%
2015 2.903.300.000 24.12%
2016 2.854.000.000 -1.73%
2017 3.091.800.000 7.69%
2018 3.176.400.000 2.66%
2019 3.252.500.001 2.34%
2020 4.952.800.000 34.33%
2021 5.624.300.000 11.94%
2022 4.385.100.000 -28.26%
2023 3.404.800.000 -28.79%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Laboratory Corporation of America Holdings Net Profit
Year Net Profit Growth
2012 583.100.000
2013 573.800.000 -1.62%
2014 511.200.000 -12.25%
2015 437.600.000 -16.82%
2016 711.800.000 38.52%
2017 1.227.100.000 41.99%
2018 883.700.000 -38.86%
2019 823.800.000 -7.27%
2020 1.556.100.000 47.06%
2021 2.377.300.000 34.54%
2022 1.279.100.000 -85.86%
2023 733.200.000 -74.45%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Laboratory Corporation of America Holdings Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 6
2013 6 16.67%
2014 6 -20%
2015 4 -25%
2016 7 33.33%
2017 12 45.45%
2018 9 -37.5%
2019 8 0%
2020 16 46.67%
2021 24 37.5%
2022 14 -84.62%
2023 8 -62.5%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Laboratory Corporation of America Holdings Free Cashflow
Year Free Cashflow Growth
2012 667.600.000
2013 616.500.000 -8.29%
2014 535.500.000 -15.13%
2015 726.600.000 26.3%
2016 918.200.000 20.87%
2017 1.185.200.000 22.53%
2018 925.600.000 -28.05%
2019 1.044.500.000 11.38%
2020 1.753.600.000 40.44%
2021 2.649.200.000 33.81%
2022 1.474.000.000 -79.73%
2023 280.000.000 -426.43%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Laboratory Corporation of America Holdings Operating Cashflow
Year Operating Cashflow Growth
2012 841.400.000
2013 818.700.000 -2.77%
2014 739.000.000 -10.78%
2015 982.400.000 24.78%
2016 1.197.100.000 17.94%
2017 1.498.100.000 20.09%
2018 1.305.400.000 -14.76%
2019 1.444.700.000 9.64%
2020 2.135.300.000 32.34%
2021 3.109.600.000 31.33%
2022 1.955.900.000 -58.99%
2023 384.900.000 -408.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Laboratory Corporation of America Holdings Capital Expenditure
Year Capital Expenditure Growth
2012 173.800.000
2013 202.200.000 14.05%
2014 203.500.000 0.64%
2015 255.800.000 20.45%
2016 278.900.000 8.28%
2017 312.900.000 10.87%
2018 379.800.000 17.61%
2019 400.200.000 5.1%
2020 381.700.000 -4.85%
2021 460.400.000 17.09%
2022 481.900.000 4.46%
2023 104.900.000 -359.39%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Laboratory Corporation of America Holdings Equity
Year Equity Growth
2012 2.738.100.000
2013 2.510.699.999 -9.06%
2014 2.838.200.000 11.54%
2015 4.960.000.000 42.78%
2016 5.521.000.000 10.16%
2017 6.824.899.999 19.11%
2018 6.990.500.000 2.37%
2019 7.587.100.000 7.86%
2020 9.457.299.999 19.78%
2021 10.294.000.000 8.13%
2022 10.115.500.000 -1.76%
2023 7.892.500.000 -28.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Laboratory Corporation of America Holdings Assets
Year Assets Growth
2012 6.795.000.000
2013 6.965.900.000 2.45%
2014 7.301.800.000 4.6%
2015 14.104.700.000 48.23%
2016 14.247.000.000 1%
2017 16.673.000.000 14.55%
2018 16.185.300.000 -3.01%
2019 18.046.400.000 10.31%
2020 20.071.700.000 10.09%
2021 20.385.400.000 1.54%
2022 20.155.100.000 -1.14%
2023 16.886.000.000 -19.36%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Laboratory Corporation of America Holdings Liabilities
Year Liabilities Growth
2012 4.056.900.000
2013 4.455.200.000 8.94%
2014 4.463.600.000 0.19%
2015 9.144.700.000 51.19%
2016 8.726.000.000 -4.8%
2017 9.848.100.000 11.39%
2018 9.194.800.000 -7.11%
2019 10.459.300.000 12.09%
2020 10.614.400.000 1.46%
2021 10.091.400.000 -5.18%
2022 10.039.600.000 -0.52%
2023 8.993.500.000 -11.63%

Laboratory Corporation of America Holdings Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
147.37
Net Income per Share
7.16
Price to Earning Ratio
31.29x
Price To Sales Ratio
1.49x
POCF Ratio
13.89
PFCF Ratio
19.37
Price to Book Ratio
2.47
EV to Sales
1.43
EV Over EBITDA
10.43
EV to Operating CashFlow
13.06
EV to FreeCashFlow
18.63
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
19,03 Bil.
Enterprise Value
18,30 Bil.
Graham Number
120.87
Graham NetNet
-74.66

Income Statement Metrics

Net Income per Share
7.16
Income Quality
2.12
ROE
0.07
Return On Assets
0.02
Return On Capital Employed
0.08
Net Income per EBT
0.73
EBT Per Ebit
0.51
Ebit per Revenue
0.09
Effective Tax Rate
0.33

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.25
Operating Profit Margin
0.09
Pretax Profit Margin
0.04
Net Profit Margin
0.03

Dividends

Dividend Yield
0.16
Dividend Yield %
16.14
Payout Ratio
0.41
Dividend Per Share
36.17

Operating Metrics

Operating Cashflow per Share
16.14
Free CashFlow per Share
11.31
Capex to Operating CashFlow
-0.3
Capex to Revenue
-0.03
Capex to Depreciation
-0.82
Return on Invested Capital
0.08
Return on Tangible Assets
0.09
Days Sales Outstanding
58.87
Days Payables Outstanding
27.14
Days of Inventory on Hand
18.12
Receivables Turnover
6.2
Payables Turnover
13.45
Inventory Turnover
20.15
Capex per Share
-4.83

Balance Sheet

Cash per Share
8,38
Book Value per Share
90,63
Tangible Book Value per Share
-19.74
Shareholders Equity per Share
90.63
Interest Debt per Share
52.06
Debt to Equity
0.57
Debt to Assets
0.27
Net Debt to EBITDA
-0.41
Current Ratio
1.36
Tangible Asset Value
-1,72 Bil.
Net Current Asset Value
-5,04 Bil.
Invested Capital
0.57
Working Capital
1,05 Bil.
Intangibles to Total Assets
0.57
Average Receivables
2,05 Bil.
Average Payables
0,70 Bil.
Average Inventory
474450000
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Laboratory Corporation of America Holdings Dividends
Year Dividends Growth
2022 0
2023 35 100%

Laboratory Corporation of America Holdings Profile

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

CEO
Mr. Adam H. Schechter
Employee
56.950
Address
358 South Main Street
Burlington, 27215

Laboratory Corporation of America Holdings Executives & BODs

Laboratory Corporation of America Holdings Executives & BODs
# Name Age
1 Mr. Mark S. Schroeder
Executive Vice President, President of Diagnostics Laboratories & Chief Operating Officer
70
2 Mr. Adam H. Schechter
President, Chief Executive Officer & Chairman
70
3 Mr. Glenn A. Eisenberg
Chief Financial Officer & Executive Vice President
70
4 Dr. Marcia T. Eisenberg Ph.D.
Chief Scientific Officer & Senior Vice President
70
5 Christin O'Donnell
Vice President of Investor Relations
70
6 Mr. Peter J. Wilkinson
Senior Vice President & Chief Accounting Officer
70
7 Ms. Sandra D. van der Vaart
Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
70
8 Dr. Brian J. Caveney J.D., M.D., M.P.H.
EVice President, President of Early Development Research Laboratories & Chief Medical Officer
70
9 Mr. Lance V. Berberian
Executive Vice President and Chief Information & Technology Officer
70
10 Ms. Amy B. Summy
Executive Vice President & Chief Marketing Officer
70

Laboratory Corporation of America Holdings Competitors